scispace - formally typeset
C

Charles A. Dinarello

Researcher at University of Colorado Denver

Publications -  1073
Citations -  152254

Charles A. Dinarello is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Interleukin & Cytokine. The author has an hindex of 190, co-authored 1058 publications receiving 139668 citations. Previous affiliations of Charles A. Dinarello include University of Guadalajara & Pennsylvania State University.

Papers
More filters
Journal ArticleDOI

Increased plasma interleukin-1 activity in women after ovulation

TL;DR: Interleukin-1 appears to have a role in normal physiological conditions as well as in disease states.
Journal ArticleDOI

Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18

TL;DR: A novel, constitutively expressed and secreted IL-18 binding protein (IL-18BP) neutralizes IL- 18 and thereby suppresses the production of IFN-gamma, resulting in reduced T-helper type 1 immune responses.
Journal ArticleDOI

Rapid responses to anakinra in patients with refractory adult-onset Still's disease

TL;DR: Refractory AOSD appears to be IL-1-mediated since anakinra decreases hematologic, biochemical, and cytokine markers and also produces rapid reductions in systemic and local inflammation.
Journal ArticleDOI

Immunoreactive interleukin-1β localization in the rat forebrain

TL;DR: It is demonstrated that IL-1β is part of a diffuse intrinsic neural system in the rat central nervous system, associated with regions involved with hypophysiotropic, autonomic, limbic and extrapyramidal functions.
Journal ArticleDOI

Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis.

TL;DR: It is demonstrated that IL-1 gene expression and synthesis occur early in the course of immune complex-induced colitis and are significantly elevated for 12 h before the appearance of PGE2 and LTB4; tissue levels ofIL-1 correlate with the degree of tissue inflammation and; specific blockade of IL-2 receptors reduces the inflammatory responses associated with experimental colitis.